After spending three terrific days in Boston, covering the BPI meeting, the GEN team is heading back home. Right before catching his train, John Sterling, Editor-in-Chief at GEN, joined Julianna LeMieux, PhD, Deputy Editor-in-Chief, and Kevin Davies, PhD, GEN‘s Editor at Large, to share their impressions of what they had learned over the past few days.

Artificial intelligenceBioprocessingGene editingGene therapy (Therapeutics)
Previous articleAVITI™ in Action: Any Scale, Any Application
Next articleSolutions for In-Process Monitoring of Critical Quality Attributes in Bioprocessing
Also of Interest
StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
WuXi Biologics Launches New Bioprocessing Platform
Accelerating Drug Development Using Medical Imaging AI
Forwarding Allogeneic Therapies
In-Line Analytical Benefits and Challenges
Analytical Technologies Evolve with Cell Therapies
Related Media
Boston and Bioprocessing: GEN Reports Live from the First Day at BPI
Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning
Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge”
Breathing Oxygen Back into the Biological Conversation
Global Single-Use Network Support Assurance of Supply
Resins Address Downstream Purification Concerns